Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
A guide to treating gait impairment with prolonged-release fampridine (Fampyra(®)) in patients with multiple sclerosis.
Does the preclinical evidence for functional remyelination following engraftment into the injured spinal cord support progression to clinical trials?
Autoantibodies against vinculin in patients with chronic inflammatory demyelinating polyneuropathy.
Use of complementary and alternative medicine in patients with cancer or multiple sclerosis: possible public health implications.
Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling.
Involvement of membrane skeletal molecules in the Schmidt-Lanterman incisure in Schwann cells.
Guillain Barré Syndrome in a multiple myeloma patient after the first course of bortezomib therapy: A case report.
Similar barriers and facilitators to physical activity across different clinical groups experiencing lower limb spasticity.
[Axonal Regeneration-related Molecules as Biomarkers for Multiple Sclerosis].
Functional course of Progressive Multifocal Leukoencephalopathy.
Visual outcomes in pediatric optic neuritis.
Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial.
Proteomics Urine Analysis of Pregnant Women Suffering from Multiple Sclerosis.
Activation of endogenous neural stem cells for multiple sclerosis therapy.
NFATc1 deficiency in T cells protects mice from experimental autoimmune encephalomyelitis.
Goals set after completing a teleconference-delivered program for managing multiple sclerosis fatigue.
Label-fusion-segmentation and deformation-based shape analysis of deep gray matter in multiple sclerosis: The impact of thalamic subnuclei on disability.
Multiple sclerosis: Study reinforces need for contraception in women taking fingolimod.
Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.
Gait characteristics of multiple sclerosis patients in the absence of clinical disability.
Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy.
Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system.
Elevation of 20-carbon long chain bases due to a mutation in serine palmitoyltransferase small subunit b results in neurodegeneration.
Translation, Cultural Adaptation and Validation of the Qualiveen-30 Questionnaire in Persian for Patients with Spinal Cord Injury and Multiple Sclerosis.
Integration of Th17- and Lymphotoxin-Derived Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate Neuroinflammation.
Pages
« first
‹ previous
…
681
682
683
684
685
686
687
688
689
…
next ›
last »